SpePharm’s Loramyc 50mg, a muco-adhesive buccal tablet of miconazole, is indicated for the treatment of oropharyngeal candidiasis (OPC) in immunocompromised patients. At the same time, Loramyc has been
This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of Reolysin given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include
Levoleucovorin for Injection is indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent
According to Compendia, Oncomine Enterprise Edition builds upon the features of Oncomine Professional and Concepts editions by integrating the ability to securely view proprietary gene expression data in
South West RDA has reported the successful expansion of Devon-based pharmaceutical in the South West. Opal Healthcare has created a new company in the region as OI Sciences.
This randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial is being conducted in healthy adults. The company anticipates that trial results will be available by end of 2008. This US
The results demonstrated that PAC-113 is effective in the treatment of oral Candidiasis and compares favorably to the efficacy demonstrated by Nystatin, a current standard of care. The
Starting last quarter, Taami enrolled its first six patients and recently initiated the fifth participating hospital. The trial comprises two treatment groups and enrolls the most complex acute
The contract is anticipated to generate $1.5 to $2 million in revenues over the next 12-18 months. The contract includes technical transfer to support GMP manufacturing, process validation,
Jonathan Houssian, CEO and founder of RxElite, said: “This investment by NPIL Pharma will allow us to maintain our strong momentum in our Sevoflurane business through continued investment
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.